These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 28724340)

  • 1. Pharmacological therapeutics in Friedreich ataxia: the present state.
    Strawser C; Schadt K; Hauser L; McCormick A; Wells M; Larkindale J; Lin H; Lynch DR
    Expert Rev Neurother; 2017 Sep; 17(9):895-907. PubMed ID: 28724340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic approaches for the treatment of Friedreich's ataxia.
    Strawser CJ; Schadt KA; Lynch DR
    Expert Rev Neurother; 2014 Aug; 14(8):949-57. PubMed ID: 25034024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New developments in pharmacotherapy for Friedreich ataxia.
    Clay A; Hearle P; Schadt K; Lynch DR
    Expert Opin Pharmacother; 2019 Oct; 20(15):1855-1867. PubMed ID: 31311349
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacotherapeutic strategies for Friedreich Ataxia: a review of the available data.
    Gunther K; Lynch DR
    Expert Opin Pharmacother; 2024 Apr; 25(5):529-539. PubMed ID: 38622054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia.
    Seznec H; Simon D; Monassier L; Criqui-Filipe P; Gansmuller A; Rustin P; Koenig M; Puccio H
    Hum Mol Genet; 2004 May; 13(10):1017-24. PubMed ID: 15028670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging therapies in Friedreich's Ataxia.
    Zesiewicz TA; Hancock J; Ghanekar SD; Kuo SH; Dohse CA; Vega J
    Expert Rev Neurother; 2020 Dec; 20(12):1215-1228. PubMed ID: 32909841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deferiprone and idebenone rescue frataxin depletion phenotypes in a Drosophila model of Friedreich's ataxia.
    Soriano S; Llorens JV; Blanco-Sobero L; Gutiérrez L; Calap-Quintana P; Morales MP; Moltó MD; Martínez-Sebastián MJ
    Gene; 2013 Jun; 521(2):274-81. PubMed ID: 23542074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Friedreich ataxia: an update on animal models, frataxin function and therapies.
    González-Cabo P; Llorens JV; Palau F; Moltó MD
    Adv Exp Med Biol; 2009; 652():247-61. PubMed ID: 20225031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skeletal Muscle Involvement in Friedreich Ataxia.
    Indelicato E; Wanschitz J; Löscher W; Boesch S
    Int J Mol Sci; 2024 Sep; 25(18):. PubMed ID: 39337401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent Advances in the Treatment Strategies of Friedreich's Ataxia: A Review of Potential Drug Candidates and their Underlying Mechanisms.
    Saini AK; Anil N; Vijay AN; Mangla B; Javed S; Kumar P; Ahsan W
    Curr Pharm Des; 2024; 30(19):1472-1489. PubMed ID: 38638052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Limitations in a frataxin knockdown cell model for Friedreich ataxia in a high-throughput drug screen.
    Calmels N; Seznec H; Villa P; Reutenauer L; Hibert M; Haiech J; Rustin P; Koenig M; Puccio H
    BMC Neurol; 2009 Aug; 9():46. PubMed ID: 19703283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding the molecular mechanisms of Friedreich's ataxia to develop therapeutic approaches.
    Schmucker S; Puccio H
    Hum Mol Genet; 2010 Apr; 19(R1):R103-10. PubMed ID: 20413654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitochondrial dysfunction in Friedreich's ataxia: from pathogenesis to treatment perspectives.
    Lodi R; Rajagopalan B; Bradley JL; Taylor DJ; Crilley JG; Hart PE; Blamire AM; Manners D; Styles P; Schapira AH; Cooper JM
    Free Radic Res; 2002 Apr; 36(4):461-6. PubMed ID: 12069111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small molecules affecting transcription in Friedreich ataxia.
    Gottesfeld JM
    Pharmacol Ther; 2007 Nov; 116(2):236-48. PubMed ID: 17826840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysregulation of cellular iron metabolism in Friedreich ataxia: from primary iron-sulfur cluster deficit to mitochondrial iron accumulation.
    Martelli A; Puccio H
    Front Pharmacol; 2014; 5():130. PubMed ID: 24917819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficient attenuation of Friedreich's ataxia (FRDA) cardiomyopathy by modulation of iron homeostasis-human induced pluripotent stem cell (hiPSC) as a drug screening platform for FRDA.
    Lee YK; Lau YM; Ng KM; Lai WH; Ho SL; Tse HF; Siu CW; Ho PW
    Int J Cardiol; 2016 Jan; 203():964-71. PubMed ID: 26625322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia.
    Rötig A; de Lonlay P; Chretien D; Foury F; Koenig M; Sidi D; Munnich A; Rustin P
    Nat Genet; 1997 Oct; 17(2):215-7. PubMed ID: 9326946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of diazoxide on Friedreich ataxia models.
    Santoro A; Anjomani Virmouni S; Paradies E; Villalobos Coa VL; Al-Mahdawi S; Khoo M; Porcelli V; Vozza A; Perrone M; Denora N; Taroni F; Merla G; Palmieri L; Pook MA; Marobbio CMT
    Hum Mol Genet; 2018 Mar; 27(6):992-1001. PubMed ID: 29325032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Designing phase II clinical trials in Friedreich ataxia.
    Rodden LN; Lynch DR
    Expert Opin Emerg Drugs; 2021 Dec; 26(4):415-423. PubMed ID: 34693848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell and gene therapy for Friedreich ataxia: progress to date.
    Evans-Galea MV; Pébay A; Dottori M; Corben LA; Ong SH; Lockhart PJ; Delatycki MB
    Hum Gene Ther; 2014 Aug; 25(8):684-93. PubMed ID: 24749505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.